MCJ (MyCancerJourney) is the first and only solution to seamlessly blend high-tech real-world data and artificial intelligence with high-touch patient support resulting in personalized shared decision-making for cancer care.
MCJ is a cloud-based advanced analytic platform that provides information tailored to a patient’s unique characteristics, clinical condition, and goals for care.
MCJ personalized high-tech analytics based on millions of real-world patients to support informed care decisions that enhance the quality of life, survival, and goal attainment while seeking to eliminate treatment that has no or limited therapeutic value.
Recent studies found that use of MCJ resulted in a 40% reduction in first year treatment cost with statistically no difference in survival while improving patient quality of life.
Patients who use MCJ have more realistic expectations, are less likely to make suboptimal treatment decisions. Oncologists who use MCJ report having better prepared patients who report higher satisfaction with their care.
MCJ's robust and expertly-validated models are based upon over 2.15 million real life cases.
MCJ's models take into account key patient factors, including age, gender, race, and comorbidities.
MCJ provides rich analytics and 5-year survivability curves with 96% probability for 15 cancer types.
Organizations that have used MCJ report up to a 40% reduction in treatment costs in the first year.
Models developed using one of the largest cancer outcomes databases derived from precisely collected information on over 2 million cases from over 500 hospitals and cancer treatment centers.
Collection and reporting standards are per the National Program of Cancer Registries (NPCR); Centers for Disease Control and Prevention (CDC); North American Association of Central Cancer Registries (NAACCR); Surveillance, Epidemiology, and End Results Program (SEER) of the National Cancer Institute (NCI); and the American College of Surgeons (ACoS).
Experts in each of the solid tumor types from The American College of Surgeons Commission on Cancer(CoC), the Centers for Disease Control and Prevention National Program of Cancer Registries (NPCR), and the SEER Program of the National Cancer Institute collaborate to clarify data fields, coding rules and instructions annually. The MCJ models are updated annually. Clinical experts in each cancer type work with our biostatisticians to determine which input variables will be utilized from the available information.
MCJ employs validated Artificial Intelligence to analyze millions of individual factors to reveal the outcomes of "people like you" for different treatment decisions. With the power of insight, you can make more informed health care decisions.
MCJ analytic platform was developed and back tested over the past decade. Experts in prognostic modeling, clinicians and statisticians have validated the models.
MCJ is currently deployed by payors/insurance companies, providers of care and self-insured employers.
MCJ provides rich analytics for 15 adult cancer types:
Bladder, breast, cervix, colon, head and neck, kidney, liver, lung, ovary, pancreas, prostate, rectum, stomach, thyroid, and uterus.
With the MCJ platform you are tapping into a real economy of scale and accessing data that otherwise would be unavailable.
Investment to deploy MCJ is minimal, and payback is almost immediate with returns that are easy to quantify.
Recent studies found that use of MCJ resulted in a 40% reduction in first year treatment cost with statistically no difference in survival while improving patient quality of life.
To request a consultation or discover more about MCJ, please reach us via email or click the link below and complete our online contact form.
